Medically reviewed by Dr. Ajit Jha, MBBS, MD Medicine | Member, Editorial Board, International Journal of Diabetes and Endocrinology (IJDE)
If you have been diagnosed with polycystic ovary syndrome, the condition you know by the name PCOS has just been officially renamed. International medical bodies have updated the terminology to Polycystic Metabolic and Ovarian Syndrome, shortened to PMOS. The name change is not cosmetic. It reflects a fundamental shift in how doctors now understand this condition — and it has real consequences for how it is diagnosed, treated, and managed.
PCOS is one of the most common hormonal conditions in the world, affecting roughly one in ten women of reproductive age. In India alone, estimates suggest between 20 and 25 percent of women have some form of the condition — making it more common than diabetes in that age group. Yet for decades, the name itself was misleading. It implied that the core problem was cysts on the ovaries. The new evidence says otherwise.
Why the Name Had to Change
The original name, polycystic ovary syndrome, was coined in the 1930s based on the visual appearance of ovaries under early ultrasound technology. The ovaries appeared to have multiple small follicles — which clinicians called cysts. The name stuck, even as research increasingly showed that the cysts were a symptom, not the cause.
What researchers now understand is that PMOS is primarily a metabolic and endocrine disorder. Its root driver in the majority of cases is insulin resistance — the same mechanism underlying type 2 diabetes. When the body cannot use insulin efficiently, it triggers a cascade of hormonal disruptions. Androgen levels rise. Ovulation becomes irregular or stops. The ovaries develop multiple follicles that fail to mature properly. The cysts are downstream of the real problem, not the source of it.
The new name — Polycystic Metabolic and Ovarian Syndrome — captures this more accurately. It puts metabolic dysfunction at the centre of the diagnosis.
What This Means in Practice
PMOS: What Changes for Women
Metabolic screening becomes standard. Women with PMOS should now routinely be tested for insulin resistance, blood glucose, and cardiovascular risk — not just reproductive hormones.
Ovarian ultrasound alone is no longer sufficient. Diagnosis requires evidence of hormonal imbalance or metabolic dysfunction, not just the presence of follicles on ultrasound.
Treatment shifts toward metabolic intervention. Diet, exercise, and insulin-sensitising approaches now take centre stage — because fixing insulin resistance often resolves the hormonal symptoms that follow.
Long-term disease risk gets more attention. Women with PMOS have significantly higher lifetime risk of type 2 diabetes, cardiovascular disease, and endometrial cancer. The new framework means these risks are addressed from the moment of diagnosis.
The Insulin Connection
Understanding insulin resistance is the key to understanding PMOS. In a healthy body, insulin signals cells to absorb glucose from the bloodstream for energy. In insulin resistance, cells stop responding properly to that signal. The pancreas compensates by producing more insulin. The excess insulin drives the ovaries to produce more androgens — male sex hormones including testosterone. Elevated androgens disrupt ovulation, cause acne, trigger excess hair growth, and suppress fertility.
This means that in many women with PMOS, addressing insulin resistance directly — through diet, exercise, and in some cases medication — can dramatically improve hormonal symptoms without directly targeting those hormones at all. This is a powerful reframe. The ovaries are not the problem. The metabolic system is.
What Women With PCOS or PMOS Should Do Now
If you have been diagnosed with PCOS, your diagnosis still stands. The condition has not changed — only the name and the medical understanding of its root cause have been updated. Here is what the updated guidance recommends:
First, ask your doctor for a full metabolic panel. This should include fasting insulin, fasting glucose, HbA1c, lipid profile, and blood pressure assessment. Many women with PCOS have significant insulin resistance that has never been formally tested.
Second, prioritise diet and exercise interventions. A low-glycaemic diet — one that minimises blood sugar spikes — has strong clinical evidence for improving PMOS symptoms. Even modest weight loss of 5 to 10 percent of body weight can restore ovulation in some women.
Third, consider clinical-grade supplements that support insulin sensitivity. Berberine, a compound derived from the barberry plant, has been studied in multiple clinical trials for PCOS and PMOS. A 2024 meta-analysis found that berberine improved menstrual regularity, reduced androgen levels, and improved insulin sensitivity in women with PCOS — with an effect size comparable to metformin in some studies.
Supplement Recommendation for PMOS
For women looking to support insulin sensitivity naturally, berberine has the strongest clinical evidence for PCOS and PMOS management. I recommend checking out a trusted berberine supplement on Amazon India — it pairs well with dietary changes and regular movement. See the recommended option here.
The Bigger Picture
The renaming of PCOS to PMOS is a signal that medicine is catching up with what the data has been showing for years. This is a whole-body, metabolic condition — not a reproductive quirk confined to the ovaries. Women deserve to be treated with that full picture in mind.
The shift also reduces stigma. The word “polycystic” confused many women into believing their ovaries were permanently damaged or structurally abnormal. The new name makes clear that the problem is metabolic — and metabolic problems respond to metabolic solutions.
If you or someone you know has PCOS, now is a good time to revisit the diagnosis with updated knowledge. Ask the right questions. Get the metabolic tests done. And know that this condition, with the right approach, is highly manageable.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.
Dr. Ajit Jha is a practising physician with MBBS and MD Medicine qualifications, an IMA Lifetime Member, and a member of the Editorial Board of the International Journal of Diabetes and Endocrinology (IJDE).
📖 Related Articles